Novo CEO explains rebranding and obesity strategy shift

Novo Nordisk announced a series of strategic changes that it described as the beginning of a new chapter for the company, amid growing competition from U.S. drugmaker Eli Lilly. The Danish firm said it would shift its focus toward expanding its obesity‑treatment portfolio and strengthening its diabetes‑care pipeline, while also tightening its cost structure and accelerating product launches in key emerging markets.

The company named a new chief executive officer and outlined a five‑year plan that includes increased investment in research and development, a renewed emphasis on digital health solutions, and a partnership strategy aimed at securing early access to novel therapies. Analysts note that the move comes as Eli Lilly’s recently approved GLP‑1 agonist gains traction, threatening Novo Nordisk’s market share in the global diabetes and obesity segments. The Danish drugmaker also highlighted its goal of achieving a 10 % growth in sales volume by 2028, supported by a projected pipeline of at least three new approvals.

With the announcement, Novo Nordisk signals its intent to remain a leading player in the highly competitive endocrinology market. By redefining its strategic priorities and leveraging its strong R&D capabilities, the company aims to counter Eli Lilly’s advances and maintain its position as a global leader in diabetes and obesity treatment.